| Patents for C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629) |
|---|
| 08/15/2002 | WO2001028545A9 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 08/15/2002 | WO2001019856A3 Secreted human proteins, polynucleotides encoding them and methods of using the same |
| 08/15/2002 | WO1999064067A9 Vaccine |
| 08/15/2002 | US20020112255 Transgenic mice containing intestinal alkaline phosphatase gene disruptions |
| 08/15/2002 | US20020112253 Acetyl-coenzyme a carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action |
| 08/15/2002 | US20020112252 See-through medaka |
| 08/15/2002 | US20020111695 Reconstituted mineralized cartilage tissue |
| 08/15/2002 | US20020111676 Cardiovascular components for transplantation and methods of making thereof |
| 08/15/2002 | US20020111475 Flt3-L mutants and methods of use |
| 08/15/2002 | US20020111473 Novel g protein coupled receptor |
| 08/15/2002 | US20020111472 T1-r ligand iii |
| 08/15/2002 | US20020111470 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof |
| 08/15/2002 | US20020111469 Polypeptide for use in the treatment of tumors, lung defects, inflammation and heart defects |
| 08/15/2002 | US20020111463 Human neuronal nicotinic acetylcholine receptor compositions and methods employing same |
| 08/15/2002 | US20020111460 Polypeptide for use in the treatment of blood coagulation, proteolysis, complement activation, fertilization, and hormone generation defects; for use as wound healing agents |
| 08/15/2002 | US20020111306 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| 08/15/2002 | US20020111299 Family of peptides known as xenoxins |
| 08/15/2002 | US20020110914 Platelet suspensions and methods for resuspending platelets |
| 08/15/2002 | US20020110913 Human cell culture for use in the generation of erythropoietin |
| 08/15/2002 | US20020110912 Cancer cells for use as animal model in the treatment of mouth cancer |
| 08/15/2002 | US20020110910 Isolation procedure and optimized media solution to enhance long-term survival of cells |
| 08/15/2002 | US20020110898 Attenuating endogenous genes in cell; obtain cell, transform with vectors conding restriction enzymes, recover and propagate transformed cells |
| 08/15/2002 | US20020110897 Nucleotide squences coding preferential operon for use in the generation of an antibiotics and desoamine |
| 08/15/2002 | US20020110895 Nucleotide sequences coding enzymatic polypeptide for use in treatment of thrombosis and in the immune defects |
| 08/15/2002 | US20020110889 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/15/2002 | US20020110888 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/15/2002 | US20020110883 Novel motor proteins and methods for their use |
| 08/15/2002 | US20020110870 Therapeutic applications for CCR5 chemokine receptors |
| 08/15/2002 | US20020110868 Tumor necrosis factor ptotein; for use in the treatment of rheumatic diseases and arthritis |
| 08/15/2002 | US20020110866 Nucleotide sequences coding viral capsid protein; for use in the diagnosis, treatment and/or vaccination |
| 08/15/2002 | US20020110865 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses |
| 08/15/2002 | US20020110863 Nucleotide sequences coding enzymatic polypeptide for use as tool genetic engineering |
| 08/15/2002 | US20020110861 Expression vectors for use as tools for controlling gene expression in genetic engineering |
| 08/15/2002 | US20020110859 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/15/2002 | US20020110858 Lymphocytic membrane proteins |
| 08/15/2002 | US20020110853 Polypeptide; for use in the treatment of tumors |
| 08/15/2002 | US20020110840 Detecting modulators of interferon generation; obtain cells, incubate with modulator, monitor concentration of inflammatory cytokine, amplified cytokine concentration indicates modulators |
| 08/15/2002 | US20020110836 PD-L2 molecules: novel PD-1 ligands and uses therefor |
| 08/15/2002 | US20020110830 Monitoring vascular endothelial growth factor activity in a sample; obtain sample, incubate with preferential genetically engineered cells, detecting expression of the reporter element, expression indicates growth factor activity |
| 08/15/2002 | US20020110824 Screening for modulators of dermatitis; obtain tissue sample, incubate with modulator, monitor expression of preferential cytokine, presence of cytokine indicates dermatitis |
| 08/15/2002 | US20020110822 Classification of preferential dermatitus; obtain skin sample, recover nucleotide sequences, monitor expression pattern of cytokine, classify dermatitis |
| 08/15/2002 | US20020110805 Peptide for use in the treatment of glomerulonephritis, psoriasis, leukemia, antherosclerosis, autoimmune diseases, inflammatory, arthritic, asthmatic, and fibrotic disorders |
| 08/15/2002 | US20020110608 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 08/15/2002 | US20020110559 Confering an immune response to a tumor cell in a mammal by administering antibody which binds to aspartyl (asparaginyl) beta hydroxylase (HAAH) |
| 08/15/2002 | US20020110546 Implanting cells of an immortalized human neuro-derived fetal cell line into the host for therapy |
| 08/15/2002 | US20020110545 Adenovector pharmaceutical composition |
| 08/15/2002 | US20020110544 Osteoarthritis cartilage regeneration |
| 08/15/2002 | CA2437727A1 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 08/15/2002 | CA2437717A1 G-protein coupled receptors |
| 08/15/2002 | CA2437648A1 Multipotent o-2a progenitors from the neurohypophysis |
| 08/15/2002 | CA2437577A1 Human sphingosine-1-phosphate phosphatase |
| 08/15/2002 | CA2437573A1 Methods for diagnosing and treating heart disease |
| 08/15/2002 | CA2437572A1 Method for the production of plant seed with modified fibre content and modified seed coat |
| 08/15/2002 | CA2437571A1 Receptors and membrane-associated proteins |
| 08/15/2002 | CA2437570A1 Methods for diagnosing and treating heart disease |
| 08/15/2002 | CA2437503A1 Hepatitis b virus treatment |
| 08/15/2002 | CA2437497A1 Lipid-associated molecules |
| 08/15/2002 | CA2437484A1 Ragweed allergens |
| 08/15/2002 | CA2437453A1 Conformationally abnormal forms of tau proteins and specific antibodies thereto |
| 08/15/2002 | CA2437434A1 Method for identifying compounds modulating reverse cholesterol transport |
| 08/15/2002 | CA2437212A1 Methods and devices for tissue repair |
| 08/15/2002 | CA2437185A1 Timm8b-related protein |
| 08/15/2002 | CA2436986A1 Ter sites and ter binding proteins |
| 08/15/2002 | CA2436470A1 Intracellular signaling molecules |
| 08/15/2002 | CA2435814A1 Multi-sample fermentor and method of using same |
| 08/15/2002 | CA2435620A1 Enteric nervous system derived stem and progenitor cells and uses thereof |
| 08/15/2002 | CA2434944A1 Secreted proteins |
| 08/15/2002 | CA2433439A1 Proteins and nucleic acids encoding same |
| 08/14/2002 | EP1231277A2 Biocompatible implant for in vivo formation of a neo-organ |
| 08/14/2002 | EP1231276A1 Method for purifying proteins and/or biomolecule of protein complexes |
| 08/14/2002 | EP1231266A1 Arabidopsis-origin gdp-4-keto-6-deoxy-d-mannose-3,5-epimerase-4-reductase gene |
| 08/14/2002 | EP1231265A2 A receptor protein tyrosine kinase |
| 08/14/2002 | EP1231263A1 Multipotent O-2A progenitors from the neurohypophysis |
| 08/14/2002 | EP1231262A1 Method of in vitro culture of lymphocytes and gene therapy compositions |
| 08/14/2002 | EP1231261A2 A method for isolating cells that express FLK-1 receptors on their surface |
| 08/14/2002 | EP1231260A2 A method for isolating cells that express FLK-2 receptors on their surface |
| 08/14/2002 | EP1231259A2 Transferring materials into cells using porous silicon |
| 08/14/2002 | EP1230939A1 Bioartificial vascularised tissue matrix and bioartificial vascularised tissue |
| 08/14/2002 | EP1230551A2 Methods to identify compounds that modulate neuronal activity |
| 08/14/2002 | EP1230394A1 Lentiviral vector transduction of hematopoietic stem cells |
| 08/14/2002 | EP1230379A2 Regulating endogenous inhibitor at atp synthase |
| 08/14/2002 | EP1230378A2 An oncolytic adenovirus |
| 08/14/2002 | EP1230374A2 Modification of polysaccharide containing materials |
| 08/14/2002 | EP1230369A2 Polypeptide hormone phosphatonin |
| 08/14/2002 | EP1230368A2 Mammalian receptor proteins; related reagents and methods |
| 08/14/2002 | EP1230367A1 19 human secreted proteins |
| 08/14/2002 | EP1230365A2 Bt toxin receptors from lepidopteran insects and methods of use |
| 08/14/2002 | EP1230364A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 08/14/2002 | EP1230361A2 G protein-coupled receptors expressed in human brain |
| 08/14/2002 | EP1230360A2 15 human secreted proteins |
| 08/14/2002 | EP1230357A2 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions |
| 08/14/2002 | EP1230356A2 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 08/14/2002 | EP1230354A2 Permanent amniocyte cell line, the production thereof and its use for producing gene transfer vectors |
| 08/14/2002 | EP1230349A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 08/14/2002 | EP1230346A2 Method for enhancing t cell reactivity toward tumour antigens |
| 08/14/2002 | EP1230342A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 08/14/2002 | EP1230271A1 Hedgehog fusion proteins and uses |
| 08/14/2002 | EP1230268A2 Heteroclitic analogs of class i epitopes |
| 08/14/2002 | EP1230266A1 Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies |
| 08/14/2002 | EP1230264A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |